CERES BRAIN Therapeutics’ Post

The GCAT - Genomes for life cohort is now part of the CORDELIA consortium, a strategic collaboration aimed at creating the largest cardiovascular genetic study in Southern Europe. This initiative is integrated into the IGTP CORE transversal program, which promotes innovative and translational research, implements new knowledge in clinical practice, and enhances population health. CORDELIA, supported by the Instituto de Salud Carlos III, unites 35 cohorts across the Iberian Peninsula, encompassing 196,000 participants and 115,000 DNA samples, with 20,000 contributed by GCAT. The study seeks to determine cardiovascular disease risk through whole-genome analysis, with a strong focus on understanding lifestyle, genetic, and environmental factors to improve prediction, prevention, and treatment methods. GCAT's incorporation into the consortium marks a strategic move to enhance the scope of cardiovascular genetic research, leveraging its large population cohort and expertise in genomic health studies, further strengthening IGTP's position as a leading centre in genomic and public health research. Learn more about this collaboration: https://lnkd.in/dyanyHmN #CardiovascularHealth #Genomics #PopulationHealth

The Sant Pau Research Institute achieves three international research projects on minority diseases🚀 They have been granted by the European Joint Programme on Rare Diseases and address various challenges in rare and autoimmune diseases, with a focus on improving diagnosis and treatment. ➡️The projects are: 🔬ADTKD-Net: focuses on autosomal dominant tubulointerstitial nephropathy that represents a diagnostic and therapeutic challenge. Researchers from the Nephrology group, led by Dr. Roser Torra Balcells, will work on the creation of a European registry of cases to better understand the progression of the disease and identify prognostic biomarkers, opening the door to future personalised therapies. ✍🏽OptiMyG: studies myasthenia gravis, an autoimmune disease that affects signal transmission between nerves and muscles. Through population studies, national registries and international collaborations, this project - in which Dr. Eduard Gallardo, researcher of the Neuromuscular Diseases group, participates - seeks to identify long-term clinical predictors, evaluate the efficacy of different treatments and develop immunological biomarkers. 🧠CADANHIS: focuses on CADASIL, an inherited disease that causes stroke and vascular dementia. This international project brings together experts from different countries, including Dr. Israel Fernández and Dr. Elena Muiño Acuña, from the Pharmacogenomics and Genetics of Stroke group. The main objective is to develop new diagnosis and treatment strategies. #Research #Biomedicine #RareDiseases https://lnkd.in/dJrh6-2Z

Did you know CRISPR iPS cells are transforming Alzheimer’s research? 🧠✨ We’ve partnered with the The National Institutes of Health on the iPSC Neurodegenerative Disease Initiative (iNDI) project to advance neurodegenerative disease studies. Discover how industrialized CRISPR editing is fueling breakthroughs in Alzheimer’s research. Download the case study now: https://hubs.ly/Q030m_tN0 #CRISPR #iPSCells #AlzheimersResearch #NeurodegenerativeDisease #GeneEditing #BiomedicalResearch

Excited to share our paper published in Nature Communications after four years of work‼ Rebeca Martínez, Pablo Sacristán-Gómez and me, Nuria Sánchez de la Blanca Carrero, as co-first authors in Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, used spatial transcriptomics to reveal new molecular signatures and pathological subpopulations of cells in autoimmune thyroid diseases. 🔎 This project was in collaboration with Holger Heyn's and Fatima Sanchez-Cabo's groups. 💻 #spatialtranscriptomics #scRNAseq #thyroid #autoimmunity 📌 https://lnkd.in/e73hD2eR

Mayo Clinic’s Center for Individualized Medicine has achieved a significant milestone with its Tapestry study, generating the clinic’s largest-ever collection of exome data, which include genes that code for proteins — key to understanding health and disease. Read More: https://lnkd.in/dG9SVKud Led by Konstantinos Lazaridis, M.D., the study analyzed DNA from over 100,000 participants from diverse backgrounds, providing important insights into certain genetic predispositions to support personalized and proactive medical guidance. The findings, published in Mayo Clinic Proceedings, focused on pathogenic (disease-causing) and likely pathogenic genetic variants linked to three specific conditions: hereditary breast and ovarian cancer syndrome, Lynch syndrome and familial hypercholesterolemia. #MedEdgeMEA #TapestryStudy #PersonalizedMedicine #GeneticHealth #ExomeSequencing #LifeChangingGenetics #PatientEmpowerment #PreventiveCare #BRCA1AndBRCA2, Jennifer Kemppainen, #LynchSyndrome #MayoClinicResearch Mayo Clinic Health Education & Content Services

We've just opened up the second year of our call for applications focused on PRPH2 and Associated Retinal Diseases. Share broadly with anyone who might be interested! The Foundation Fighting Blindness seeks applications for its PRPH2 and Associated Retinal Diseases (PARD) Science Award Program. The Nixon Visions Foundation, in collaboration with the Foundation Fighting Blindness, has committed funding to advance research towards potential treatments for PRPH2-associated retinal diseases. The Foundation will make awards for meritorious research proposals that advance our understanding of the biology and pathophysiology of PRPH2 in the hashtag #retina. To address gaps in knowledge, proposals that focus on the following topics are strongly encouraged: Fundamental PRPH2 biology and biochemistry, including, but not limited to: 1. PRPH2 protein-protein interactions 2. The differential role(s) of PRPH2 in rod and cone photoreceptors 3. Development of high throughput and/or saturation assays to determine the functional consequences of PRPH2 variants on protein structure and/or function and to assign pathogenicity 4. Generation and characterization of disease models (e.g., large animals) that recapitulate PRPH2-associated human disease, including maculopathies 5. Studies demonstrating proof-of-concept for therapeutic approaches, particularly mutation-agnostic approaches 6. Improved understanding of human disease heterogeneity, through understanding of genotype-phenotype relationships or identification of genetic and/or environmental modifiers The Foundation Fighting Blindness expects to fund a limited number of PARD Science Awards with an anticipated start date of April 1, 2025. Each award will provide research support up to $500K dispersed over one to three years. Eligibility Applicants must hold a Ph.D., M.D., D.M.D., D.V.M., D.O., O.D., or equivalent degree and have a faculty position or equivalent at a domestic or foreign: non-profit organization, or public or private institution, such as a university, college, medical school, hospital, research institute, or laboratory. Applicants do not have to be U.S. citizens. Individuals from underrepresented racial, ethnic and gender groups, as well as individuals with disabilities, are always encouraged to apply.

Scientists at TGen, part of City of Hope, have partnered with Vanderbilt University Medical Center and identified key blood biomarkers that could help detect and track fatty liver disease early—without painful biopsies! A fatty liver (hepatic steatosis) affects 30%+ of people worldwide and is linked to serious health issues like diabetes, liver cancer, and heart disease. This breakthrough could lead to easier, faster, and less invasive ways to monitor liver health and manage metabolic diseases. These results are part of a growing body of research aimed at understanding how metabolic diseases like MASLD develop and how they can be managed more effectively. This study represents a significant step forward in identifying functional biomarkers that could inform both diagnostics and treatment strategies for liver diseases. This research underscores the importance of combining clinical data with advanced molecular technologies to improve our understanding of complex diseases and develop more effective tools for prevention and treatment. Read more at https://lnkd.in/dERibXaC #Science #Research #Impact #Technology #LiverHealth #MedicalResearch #FattyLiver #HealthInnovation #TGen #CityOfHope #Biomarkers #Genomics #Arizona #foryoupage #fyp

TGen, a part of City of Hope, is proud of the work we have done around diabetes research. Researchers like Johanna DiStefano, Ph.D., professor and head of TGen’s Diabetes and Fibrotic Disease Unit, are committed to research that improves precision medicine for patients. TGen's research focuses on identifying the genes that cause diseases like diabetes and diabetic kidney disease. The institute uses translational genomics research to develop new diagnostics, therapies, and prognostics for diabetes and other diseases. Learn more about our research and precision medicine at TGen.org

🚨 Exciting Breakthrough in Crohn's Disease Research! 🚨 Cambridge scientists have successfully grown 'mini-guts' to better understand Crohn's disease and personalise treatments. 🧬✨ Using cells from 160 patients, the team grew over 300 organoids, giving unprecedented insight into how epigenetic changes in gut cells contribute to the disease. Click the link to read: https://lnkd.in/eNFaXBax University of Cambridge #CrohnsDisease #IBD #PersonalisedMedicine #MiniGuts #Epigenetics

🚨 Exciting News from ERDERA! 🚨 We are thrilled to pre-announce our 2025 Joint Transnational Call for Proposals focused on pre-clinical therapy studies for rare diseases using small molecules and biologicals. 🧬🌍 This call offers a unique opportunity for researchers worldwide to collaborate on groundbreaking research that can potentially improve the lives of millions affected by rare diseases. 📅 Important Dates: - Call Opens: December 10, 2024 - Pre-Proposal Deadline: February 13, 2025 💡 Key topics include novel therapies, biomarkers, and proof-of-concept studies. We're encouraging partnerships with Early Career Researchers and Patient Advocacy Organizations to create an inclusive, interdisciplinary research environment. Read more about the call details here: https://loom.ly/-YEsh3Y Stay tuned for more updates and mark your calendars for our information webinar on December 17th! Please note that this is a draft announcement and the list of funders is not final. #RareDiseases #ResearchFunding #Collaboration #JTC2025 #ERDERA #ScientificResearch #Innovation #Healthcare #HorizonEurope European Health and Digital Executive Agency (HaDEA) EU Science, Research and Innovation Inserm Transfert INSERM EURORDIS-Rare Diseases Europe ANR, the French National Research Agency Fondazione Telethon ZonMw EATRIS Greater Paris University Hospitals - AP-HP Foundation For Rare Diseases RARE DISEASES INTERNATIONAL Teamit Daria Julkowska Yanis Mimouni